KAS
KRYS icon

Kemnay Advisory Services’s Krystal Biotech KRYS Stock Holding History

Kemnay Advisory Services’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$86.2K Buy
232
+16
+7% +$4.78K 0.01% 187
2026
Q1 		$55.8K Buy
216
+132
+157% +$35.1K 0.01% 229
2025
Q4 		$20.7K Buy
+84
New +$17.7K ﹤0.01% 533

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Kemnay Advisory Services's KRYS Position: Q2 2026 in Review

Kemnay Advisory Services increased its Krystal Biotech (KRYS) stake by 7.4% in Q2 2026, buying an estimated $4.78K and bringing the position to 232 shares worth $86.2K. The position accounts for 0.01% of the portfolio, ranked #187.

Kemnay Advisory Services first reported a position in KRYS in Q4 2025 and has held it in 3 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Kemnay Advisory Services held 232 shares of Krystal Biotech worth $86.2K as of Q2 2026.
  • Kemnay Advisory Services bought 16 Krystal Biotech shares in Q2 2026, an estimated $4.78K.
  • Krystal Biotech made up 0.01% of Kemnay Advisory Services's portfolio in Q2 2026, its #187 holding.
  • Kemnay Advisory Services first reported a position in Krystal Biotech in Q4 2025 and has held it in 3 quarters since.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Kemnay Advisory Services's 13F filing for Q2 2026, filed 14 Aug 2026.